Treatment of Early Stage SCLC

被引:0
|
作者
Jassem, Jacek [1 ]
机构
[1] Med Univ Gdansk, Dept & Clin Oncol & Radiotherapy, Gdansk, Poland
关键词
small cell lung cancer; Radiotherapy; combined modality treatment; CELL LUNG-CANCER; PROPHYLACTIC CRANIAL IRRADIATION; THORACIC RADIOTHERAPY; COMPLETE REMISSION; CHEMOTHERAPY; METAANALYSIS;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
MTE32.01
引用
收藏
页码:S159 / S159
页数:1
相关论文
共 50 条
  • [1] Surgery Is Associated with Favorable Outcome in Patients with Early Stage SCLC - Retrospective Institutional Experience
    Klikovits, T.
    Sinn, K.
    Gschwandtner, E.
    Kasbauer, N.
    Taghavi, S.
    Klepetko, W.
    Hoda, M. A.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1025 - S1026
  • [2] New SCLC treatment
    Gourd, Katherine
    LANCET ONCOLOGY, 2018, 19 (07): : 866 - 866
  • [3] Demographics, clinical characteristics, treatment (tx) patterns and clinical outcomes for patients ( pts) with limited-stage SCLC (LS-SCLC)
    Chiang, A. C.
    Salomonsen, R. J-B.
    Wang, A.
    Holland, R.
    Cai, L.
    Xiao, Y.
    Sadow, S.
    Davey, K.
    Iyengar, P.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S132 - S133
  • [4] Serplulimab With Chemotherapy in Extensive-Stage SCLC
    Choudhury, Noura J.
    Riely, Georgory J.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 328 (12): : 1205 - 1207
  • [5] Atezolizumab: A Review in Extensive-Stage SCLC
    Frampton, James E.
    DRUGS, 2020, 80 (15) : 1587 - 1594
  • [6] Durvalumab: A Review in Extensive-Stage SCLC
    Zaina T. Al-Salama
    Targeted Oncology, 2021, 16 : 857 - 864
  • [7] Atezolizumab: A Review in Extensive-Stage SCLC
    James E. Frampton
    Drugs, 2020, 80 : 1587 - 1594
  • [8] Durvalumab: A Review in Extensive-Stage SCLC
    Al-Salama, Zaina T.
    TARGETED ONCOLOGY, 2021, 16 (06) : 857 - 864
  • [9] TREATMENT OF LOCALLY ADVANCED SCLC
    Kubota, Kaoru
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S439 - S439
  • [10] TREATMENT OF SCLC - CONSENSUS NEEDED
    ANTOINE, FS
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (24) : 1856 - 1858